{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:00Z","timestamp":1792271340620,"version":"4.4.0"},"reference-count":84,"publisher":"Informa UK Limited","issue":"19","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.2217\/fon-2022-0162","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T13:10:06Z","timestamp":1652879406000},"page":"2415-2431","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma"],"prefix":"10.1080","volume":"18","author":[{"given":"Daanish","family":"Hoda","sequence":"first","affiliation":[{"name":"Intermountain Healthcare,\rSalt Lake City, UT,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Richards","sequence":"additional","affiliation":[{"name":"Cell Therapy & Transplant Program, Division of Hematology-Oncology & Abramson Cancer Center,University of Pennsylvania,\rPhiladelphia,\rPA 19104,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A","family":"Faber","sequence":"additional","affiliation":[{"name":"Transplant & Cellular Therapy Program,Oncology\/Hematology Care,\rUSA"},{"name":"Adult BMT & Cellular Therapy Program,University of Cincinnati,\r2600 Clifton Ave,\rCincinnati,\rOH 45221,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Deol","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Center,\r4100 John R St,\rDetroit,\rMI 48201,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-2737","authenticated-orcid":false,"given":"Bradley D","family":"Hunter","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare,\rSalt Lake City, UT,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Weber","sequence":"additional","affiliation":[{"name":"Cell Therapy & Transplant Program, Division of Hematology-Oncology & Abramson Cancer Center,University of Pennsylvania,\rPhiladelphia,\rPA 19104,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"DiFilippo","sequence":"additional","affiliation":[{"name":"Cell Therapy & Transplant Program, Division of Hematology-Oncology & Abramson Cancer Center,University of Pennsylvania,\rPhiladelphia,\rPA 19104,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Henderson-Clark","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Center,\r4100 John R St,\rDetroit,\rMI 48201,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Meaux","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare,\rSalt Lake City, UT,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Crivera","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC,\r1125 Trenton-Harbourton Road,\rTitusville,\rNJ 08560,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Riccobono","sequence":"additional","affiliation":[{"name":"US Medical Affairs,Legend Biotech,\r2101 Cottontail Lane Somerset,\rNJ 08873,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Garrett","sequence":"additional","affiliation":[{"name":"US Medical Affairs,Legend Biotech,\r2101 Cottontail Lane Somerset,\rNJ 08873,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn C","family":"Jackson","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical Research & Development,\r1125 Trenton-Harbourton Road,\rTitusville,\rNJ 08560,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fowler","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC,\r1125 Trenton-Harbourton Road,\rTitusville,\rNJ 08560,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panteli","family":"Theocharous","sequence":"additional","affiliation":[{"name":"Evidera | PPD,\r7101 Wisconsin AvenueSuite 1400Bethesda,\rMD 20814,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Stewart","sequence":"additional","affiliation":[{"name":"Evidera | PPD,\r7101 Wisconsin AvenueSuite 1400Bethesda,\rMD 20814,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4873-7880","authenticated-orcid":false,"given":"Andrea L","family":"Lorden","sequence":"additional","affiliation":[{"name":"Evidera | PPD,\r7101 Wisconsin AvenueSuite 1400Bethesda,\rMD 20814,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6333-9536","authenticated-orcid":false,"given":"David L","family":"Porter","sequence":"additional","affiliation":[{"name":"Cell Therapy & Transplant Program, Division of Hematology-Oncology & Abramson Cancer Center,University of Pennsylvania,\rPhiladelphia,\rPA 19104,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8833-4544","authenticated-orcid":false,"given":"Ariel","family":"Berger","sequence":"additional","affiliation":[{"name":"Evidera | PPD,\r7101 Wisconsin AvenueSuite 1400Bethesda,\rMD 20814,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"e_1_3_6_3_1","unstructured":"American Cancer Society . Key statistics about multiple myeloma (2021). www.cancer.org\/cancer\/multiple-myeloma\/about\/key-statistics.html"},{"key":"e_1_3_6_4_1","unstructured":"Multiple Myeloma Research Foundation . Standard treatments. https:\/\/themmrf.org\/multiple-myeloma\/treatment-options\/standard-treatments\/"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/sci-2020-029"},{"key":"e_1_3_6_6_1","unstructured":"Cancer Stat Facts . Myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1105202"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147381"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3927"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6042"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418"},{"key":"e_1_3_6_12_1","unstructured":"Dana Farber Cancer Institute . Frequently asked questions about CAR T-cell therapy. www.dana-farber.org\/cellular-therapies-program\/car-t-cell-therapy\/faq-about-car-t-cell-therapy\/"},{"key":"e_1_3_6_13_1","unstructured":"ABECMA\u00ae . Highlights of prescribing information [package insert]. Bristol Myers Squibb NY USA. https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf"},{"key":"e_1_3_6_14_1","unstructured":"NIH National Cancer Institute . FDA approves BCMA-targeted CAR T-cell therapy for multiple myeloma (2014). www.cancer.gov\/news-events\/cancer-currents-blog\/2021\/fda-ide-cel-car-t-multiple-myeloma"},{"key":"e_1_3_6_15_1","unstructured":"Johnson & Johnson . Janssen presents initial results for BCMA CAR-T therapy JNJ-4528 showing early deep and high responses in the treatment of relapsed or refractory multiple myeloma (2019). www.jnj.com\/janssen-presents-initial-results-for-bcma-car-t-therapy-jnj-4528-showing-early-deep-and-high-responses-in-the-treatment-of-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_6_16_1","unstructured":"Sternberg A . Cilta-Cel earns FDA priority review for relapsed\/refractory multiple myeloma (2021). www.cancernetwork.com\/view\/cilta-cel-earns-fda-priority-review-for-relapsed-refractory-multiple-myeloma"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01001-1"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_6_20_1","first-page":"54","article-title":"CAR T-cell therapy: current practice and future solutions to optimize patient access","volume":"7","author":"Geethakumari PR","year":"2021","unstructured":"Geethakumari PR , DhakalB, RamasamyDP, KansagraAJ. CAR T-cell therapy: current practice and future solutions to optimize patient access. J. Clin. Pathways7, 54\u201362 (2021).","journal-title":"J. Clin. Pathways"},{"issue":"5","key":"e_1_3_6_21_1","first-page":"35","article-title":"Beware of the CAR-T hitches","volume":"28","author":"Ladika S","year":"2019","unstructured":"Ladika S . Beware of the CAR-T hitches. Managed Care28(5), 35\u201337 (2019).","journal-title":"Managed Care"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.12.004"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13153"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0427-6"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00469-5"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01691"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.02.012"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.02.004"},{"issue":"11","key":"e_1_3_6_29_1","first-page":"131","article-title":"Time-driven activity-based costing","volume":"82","author":"Kaplan RS","year":"2004","unstructured":"Kaplan RS , AndersonSR. Time-driven activity-based costing. Harv. Bus. Rev.82(11), 131\u2013138(2004).","journal-title":"Harv. Bus. Rev."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2017.04.013"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2016-000134"},{"key":"e_1_3_6_32_1","doi-asserted-by":"crossref","unstructured":"Kaplan RS AndersonSR. Time-driven activity-based costing (2003). https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=485443","DOI":"10.2139\/ssrn.485443"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2021.01.003"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjdsi.2015.08.007"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00394"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29743"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.06.053"},{"key":"e_1_3_6_38_1","first-page":"80","article-title":"Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing","volume":"23","author":"Pezzi TA","year":"2020","unstructured":"Pezzi TA , NingMS, ThakerNGet al. Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing. Clin. Transl. Radiat. Oncol.23, 80\u201384 (2020).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2020.02.005"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-015-4214-0"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/2151459320958202"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2018.1496309"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2018.11.004"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008765"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3350w"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.01.018"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2016.11.001"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032573"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/HCM.0b013e31827ed898"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296816684858"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2015.08.004"},{"key":"e_1_3_6_52_1","unstructured":"Salary.com. (Accessed 13September2021). https:\/\/www.salary.com\/"},{"key":"e_1_3_6_53_1","article-title":"Alabama man dies after being turned away from 43 hospitals as COVID packs ICUs, family says","author":"Bella T","year":"2021","unstructured":"Bella T . Alabama man dies after being turned away from 43 hospitals as COVID packs ICUs, family says. Washington Post (2021). www.washingtonpost.com\/health\/2021\/09\/12\/alabama-ray-demonia-hospitals-icu\/","journal-title":"Washington Post"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6936a4"},{"key":"e_1_3_6_55_1","article-title":"Hospitals swamped with delta cases struggle to care for critical patients","author":"Evans M","year":"2021","unstructured":"Evans M . Hospitals swamped with delta cases struggle to care for critical patientsWall Street Journal. (2021). www.wsj.com\/articles\/hospitals-swamped-with-delta-cases-struggle-to-care-for-critical-patients-11630661403","journal-title":"Wall Street Journal"},{"key":"e_1_3_6_56_1","unstructured":"Scott D . Americans are dying because no hospital will take them (2021). www.vox.com\/coronavirus-covid19\/2021\/9\/14\/22650733\/us-covid-19-hospitals-full-texas-alabama"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002056"},{"key":"e_1_3_6_58_1","unstructured":"Amorosi D . First FDA-approved CAR T-cell therapy for multiple myeloma hailed as \u2018game changer\u2019 (2021). www.healio.com\/news\/hematology-oncology\/20210412\/first-fdaapproved-car-tcell-therapy-for-multiple-myeloma-hailed-as-game-changer"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8013"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.01.014"},{"key":"e_1_3_6_61_1","unstructured":"OncLive . Dr Shah on the potential rationale for selecting ide-cel vs cilta-cel in multiple myeloma (2021). www.onclive.com\/view\/dr-shah-on-the-potential-rationale-for-selecting-ide-cel-vs-cilta-cel-in-multiple-myeloma"},{"key":"e_1_3_6_62_1","unstructured":"Globe Newswire . Comprehensive Analysis of 250+ Key Companies Developing 250+ Novel CAR-T Therapies: DelveInsight (20 April 2021). www.globenewswire.com\/news-release\/2021\/04\/21\/2213788\/0\/en\/Comprehensive-Analysis-of-250-Key-Companies-Developing-250-Novel-CAR-T-Therapies-DelveInsight.html"},{"key":"e_1_3_6_63_1","unstructured":"McKinsey . Driving the next wave of innovation in CAR T-cell therapies (2019). www.mckinsey.com\/industries\/life-sciences\/our-insights\/driving-the-next-wave-of-innovation-in-car-t-cell-therapies"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00317"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194789"},{"key":"e_1_3_6_66_1","first-page":"150","article-title":"Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies?","volume":"4","author":"Tang K","year":"2021","unstructured":"Tang K , NastoupilLJ. Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies?JIPO4, 150\u2013159 (2021).","journal-title":"JIPO"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.COT.0000553160.46372.2c"},{"key":"e_1_3_6_68_1","first-page":"15","article-title":"Real-world evidence (RWE) study of CAR-T agents in leukemia and lymphoma patients","volume":"39","author":"Lai LS","year":"2021","unstructured":"Lai LS , Blauer-PetersonC, DacostaByfield S, MalinJ. Real-world evidence (RWE) study of CAR-T agents in leukemia and lymphoma patients. J. Clin. Oncol.39, 15 (2021).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02103"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002118"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2020.05.005"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1715536"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00165"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.20550"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4133"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.2131"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2018.06.001"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.10.017"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.2887"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2015.008441"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.2308\/jmar-51686"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arthro.2020.12.239"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arthro.2020.11.028"},{"key":"e_1_3_6_86_1","article-title":"Time-driven activity-based costing in trauma (Poster 156)","author":"McCreary DL","year":"2017","unstructured":"McCreary DL , DugarteAJ, MarloweHK, VangS, PlowmanBL, CunninghamBP. Time-driven activity-based costing in trauma (Poster 156). J. Orthopaedic Trauma (2017). https:\/\/ota.org\/sites\/files\/legacy_abstracts\/ota17\/OTA%20AM17%20Poster%20156.pdf","journal-title":"J. Orthopaedic Trauma"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:37Z","timestamp":1719125017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":84,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.2217\/fon-2022-0162"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0162","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}